Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 18, No. 4, 2010
Issue release date: March 2011
Section title: Original Paper
Free Access
Neurosignals 2010;18:203–209

Association of the Small GTPase Rheb with the NMDA Receptor Subunit NR3A

Sucher N.J.a–c · Yu E.d · Chan S.F.d · Miri M.b · Lee B.J.b · Xiao B.e · Worley P.F.e · Jensen F.E.b, c, f
aCentre for Complementary Medicine Research, University of Western Sydney, Penrith South DC, N.S.W., Australia; bDepartment of Neurology, Division of Neuroscience, Children’s Hospital, and cDepartment of Neurology, Harvard Medical School, Boston, Mass., dSanford-Burnham Medical Research Institute, La Jolla, Calif. eDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Md., and fProgram in Neuroscience, Harvard Medical School, Boston, Mass., USA
email Corresponding Author

Prof. Nikolaus J. Sucher

The Centre for Complementary Medicine Research

University of Western Sydney, Locked Bag 1797

Penrith, NSW 2751 (Australia)

Tel. +61 2 4620 3345, Fax +61 2 4620 3017, E-Mail n.sucher@uws.edu.au

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The NMDAR subunit NR3A is most highly expressed during the second postnatal week, when synaptogenesis reaches peak levels. Genetic ablation or overexpression of the NR3A subunit negatively interferes with the maturation of cortical synapses and leads to changes in the shape and number of dendritic spines, the density of which is increased in NR3A knock-out mice and decreased in NR3A-overexpressing transgenic mice. Alterations in spine density have been linked to dysregulation of mTOR signaling and synaptic protein translation. Using a yeast two-hybrid system, we identified the mTOR-activating GTPase Rheb as an interacting protein of the NMDAR subunit NR3A. We confirmed the interaction in mammalian cells by expressing recombinant Rheb and NR3A and showed that Rheb and NR3A could be co-immunoprecipitated from synaptic plasma membranes from the developing rat brain. These data suggest that NR3A sequesters synaptic Rheb and might thus function as a break of the mTOR-dependent synaptic translation of protein.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 27, 2010
Accepted: October 20, 2010
Published online: December 07, 2010
Issue release date: March 2011

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 1424-862X (Print)
eISSN: 1424-8638 (Online)

For additional information: http://www.karger.com/NSG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.